29
Participants
Start Date
May 31, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2012
bevacizumab
Given intravenously every 2 weeks
vinorelbine
Given intravenously once a week
trastuzumab
Given intravenously once a week
Hartford Hospital, Hartford
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Faulkner Hospital, Boston
Lowell General Hospital, Lowell
New Hampshire Oncology-Hematology PA, Hooksett
Collaborators (1)
Brigham and Women's Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Massachusetts General Hospital
OTHER
Genentech, Inc.
INDUSTRY
New Hampshire Oncology-Hematology PA
UNKNOWN
Lowell General Hospital
OTHER
Hartford Hospital
OTHER
Harold J. Burstein, MD, PhD
OTHER